Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Cabaletta Bio Inc (CABA) USD0.00001

Sell:$10.87 Buy:$10.95 Change: $0.28 (2.51%)
Market closed |  Prices as at close on 26 February 2021 | Switch to live prices |
Change: $0.28 (2.51%)
Market closed |  Prices as at close on 26 February 2021 | Switch to live prices |
Change: $0.28 (2.51%)
Market closed |  Prices as at close on 26 February 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cabaletta Bio Inc. is a clinical stage biotechnology company. The Company is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company’s lead CAAR T cell product candidate are designed based on chimeric antigen receptor, and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The Company has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.

Contact details

2929 Arch St Ste 600
United States
+1 (267) 7593100

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$283.37 million
Shares in issue:
24.06 million
United States
US dollar

Key personnel

  • Steven Nichtberger
    Chairman of the Board, President, Chief Executive Officer, Co-Founder
  • Anup Marda
    Chief Financial Officer
  • Gwendolyn Binder-Scholl
    Executive Vice President, Science & Technology
  • J. Brian Stalter
    General Counsel
  • David Chang
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.